-
Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B
•
US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3Kα inhibitor currently being studied in a Phase I/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move…
-
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of its compatriot firm Intra-Cellular Therapies Inc. (NASDAQ: ITCI) for USD 132 per share in cash, amounting to a total transaction value of USD 14.6 billion. This strategic acquisition aims to bolster J&J’s presence in the…
-
GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline
•
UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has entered into an agreement with US-based biopharma IDRx, Inc. to acquire the company for an upfront payment of USD 1 billion, along with an additional USD 150 million in success-based regulatory approval milestone payments. This strategic acquisition is aimed at strengthening GSK’s portfolio in…
-
Autobio Diagnostics Partners with Boditech Med for Korean IVD Market
•
China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered Boditech Med Inc. The collaboration, which focuses on the immunoassay field, aims to leverage the respective advantages of both companies in the in vitro diagnostics (IVD) sector to develop the Korean market. No financial details…
-
Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott Laboratories (NYSE: ABT). The agreement grants the US multinational company exclusive or semi-exclusive development and commercialization rights to four biosimilars and one novel biologic drug in 69 emerging countries and regions. The deal, for which…
-
Chongqing Genrix’s Silevimig NDA Accepted for Rabies Immunization Review
•
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) has announced that a New Drug Application (NDA) filing for its silevimig (GR1801) has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The drug is intended for passive immunization in adults…
-
Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series
•
US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies…
-
Hengrui and Kailera Announce Positive Phase II Results for HRS9531 in Weight Loss
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc. have jointly announced positive results from a Phase II weight loss study for HRS9531, a GLP-1/GIP receptor dual agonist. The study evaluated the drug at an 8 mg dose, which achieved significant weight loss and…
-
Gentize Biopharma Raises $13.64M in Pre-Series A for Vaccine Development
•
Gentize Biopharma, a clinical-stage vaccine developer based in Nanjing, has reportedly raised close to RMB 100 million (USD 13.64 million) in a Pre-Series A financing round. The round was solely funded by Hyfinity Investments, highlighting the investor’s confidence in Gentize’s innovative vaccine portfolio. Financing and Future PlansThe proceeds from this…
-
Roche’s VENTANA Kappa and Lambda Dual ISH Test Gains FDA Clearance
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing clearance from the United States Food and Drug Administration (FDA) for its highly-sensitive in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail. This follows the test’s CE Mark approval in…
-
Illumina Partners with NVIDIA to Advance Multiomic Data Analysis
•
US-based genomics giant Illumina (NASDAQ: ILMN) has announced a strategic partnership with chip manufacturer NVIDIA (NASDAQ: NVDA) to advance technology platforms for the analysis and interpretation of multiomic data. This collaboration aims to accelerate progress in clinical research, genomics AI development, and drug discovery, leveraging the strengths of both companies…
-
Leqembi Autoinjector Advances with FDA Review for Alzheimer’s Treatment
•
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) for review. The application seeks approval for the treatment of Alzheimer’s disease (AD) in patients with…
-
Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463
•
US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly and Company (NYSE: LLY) to advance its investigational drug MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). This strategic partnership aims to further develop and potentially bring to…
-
Cornerstone Robotics Raises $68.2M in Series C to Advance Surgical Robots
•
Cornerstone Robotics, an innovative surgical robot developer based in Shenzhen, has reportedly raised over RMB 500 million (USD 68.2 million) in a Series C financing round. This significant funding round was led by EQT Partners and included contributions from a prestigious group of investors, such as Qiming Venture Partners, Alpha…
-
MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer
•
China-based gene sequencing specialist MGI Tech Co., Ltd has announced that it has received a medical license from the National Medical Products Administration (NMPA) for its DNBSEQ-E25. This achievement marks the DNBSEQ-E25 as the world’s first gene sequencer based on the principle of self-luminescent sequencing biochemistry, setting a new standard…
-
Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment
•
US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI). This approval marks a significant breakthrough in the treatment of Parkinson’s…
-
Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100% of the stakes in compatriot firm Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., a genetic engineering biopharma. The transaction is valued at RMB 807.5 million (USD 110 million), marking a significant strategic move for Sansure. Acquisition…
-
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative diabetes treatment, Rybelsus (semaglutide), in China. This marks a significant milestone for the company as it expands its presence in the Chinese market. Rybelsus: A First-in-Class TherapyRybelsus holds the distinction of being the world’s first…
-
Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China
•
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received an indication extension approval from the National Medical Products Administration (NMPA) for its blockbuster drug Keytruda (pembrolizumab). The approval is for the use of Keytruda as a monotherapy for the first-line treatment of metastatic or…
-
Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I clinical study for its Category 1 chemical drug, HDM2006, in patients with advanced solid tumors. This marks a significant step forward in…
